Ichnos Sciences, a global clinical-stage biotechnology company developing multispecific antibodies for oncology, has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases. Under the agreement, Ichnos has licensed its two assets for inflammatory and immunological diseases, a key milestone in the company’s prioritizati...